Screening and Assessment of Coronary Heart Disease in HIV-Infected Patients

Priscilla Y. Hsue, MD, Co-Chair; Kathleen Squires, MD, Co-Chair; Ann F. Bolger, MD, FAHA; Bernadette Capili, DNSc, APRN, NP-C; George A. Mensah, MD, FAHA; Zelalem Temesgen, MD; Christine A. Wanke, MD; David A. Wohl, MD; for Working Group 4

Human immunodeficiency virus (HIV)–infected individuals are living longer in the era of antiretroviral therapy. As a result, they are increasingly prone to the development of concomitant chronic disease. Coronary heart disease (CHD) is the leading cause of death in the United States and Europe. Recent studies suggest that CHD rates may be increasing among HIV-infected patients (see Epidemiological Evidence for Cardiovascular Disease in HIV-Infected Patients and Relationship to Highly Active Antiretroviral Therapy, Working Group 2), and thus appropriate screening strategies for CHD in this population are needed. Recently, approaches to screening and assessment of cardiovascular disease (CVD) in HIV-infected individuals were discussed at a State of the Science Conference. Although insufficient evidence now exists to recommend a screening strategy for CHD in HIV that differs from that recommended in the non–HIV population, emerging risk factors and surrogate markers for atherosclerosis unique to the HIV population suggest specific screening categories are discussed here. The first screening strategy seeks to define the pretest likelihood of disease by performance of a complete clinical history, physical examination, and noninvasive stress tests should be preceded by the performance of a complete clinical history, physical examination, standard 12-lead ECG, and, importantly, an assessment of the pretest probability of CHD. The second screening strategy aims at the detection of established CHD, even in its earliest stages.

Screening for Cardiovascular Risk Factors

The currently available recommendations and guidelines for screening for the presence of cardiovascular risk factors in HIV-infected individuals are detailed in Table 1.1–7

The currently available recommendations and guidelines for screening for the presence of CVD risk factors in persons with HIV infection are detailed in Table 2. These recommendations take into account the evidence for CVD risk factors in persons with HIV infection are detailed in Table 2. These recommendations take into account the evidence. The decision to use invasive coronary arteriography or noninvasive stress tests should be preceded by the performance of a complete clinical history, physical examination, standard 12-lead ECG, and, importantly, an assessment of the pretest probability of CHD. Additionally, the assessment of global CHD risk can inform the selection of an appropriate initial diagnostic test.8,9
Table 1. Recommendations and Guidelines for Screening for Cardiovascular Risk Factors in the General Population

<table>
<thead>
<tr>
<th>Authority</th>
<th>Recommendation/Guideline</th>
</tr>
</thead>
<tbody>
<tr>
<td>USPSTF</td>
<td>Strongly recommends that clinicians routinely screen men ≥35 y of age and women ≥45 y of age for lipid disorders¹</td>
</tr>
<tr>
<td>NCEP ATPIII</td>
<td>In all adults ≥20 y of age, a fasting lipoprotein profile (total cholesterol, LDL-C, HDL-C, and triglycerides) should be obtained once every 5 y²</td>
</tr>
</tbody>
</table>


Calculation of the Pretest Probability of CHD and Global CHD Risk

Several electronic and paper-based tools for calculating the pretest probability have been published,¹⁰–¹² but they have not been validated specifically in the HIV population. Table 3 provides the details of 1 approach. In this model, patients with a pretest score of 0 to 8, 9 to 15, or ≥15 points are assigned a pretest probability of low, intermediate, or high, respectively.¹⁰ An intermediate pretest probability is the ideal scenario for selecting a noninvasive stress test in patients with a suspicion of CHD (ACC/AHA class I indication).⁸ Patients with a high pretest probability have a high false-negative rate on noninvasive tests; therefore, they should be referred for invasive coronary arteriography. Similarly, patients with a low pretest probability have a high false-positive rate and thus are not ideal for a noninvasive stress test such as the exercise ECG. A stress test with nuclear perfusion imaging or wall motion imaging with echocardiography may be appropriate as an initial test in this patient group, however, especially if the short-term global CHD risk is intermediate or high.⁹

Several multivariate models are available for calculating global CHD risk.¹³–¹⁵ The Framingham Risk Score,¹³ the most commonly used model, incorporates age, sex, blood pressure, low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), diabetes, and smoking to calculate the 10-year CHD risk. Low, intermediate, and high risk are defined as 10-year risk of CHD of <10%, 10% to 20%, and >20%, respectively. Patients with a low pretest probability who also have a low global CHD risk should not be referred for further diagnostic testing for CHD. However, asymptomatic patients or patients with a low pretest probability who have an intermediate CHD risk or have high-risk occupations (eg, airline pilots) are appropriate candidates for stress testing combined with nuclear or echocardiographic imaging as the initial diagnostic test.⁹ For patients with HIV, risk prediction equations that incorporate protease inhibitor (PI) exposure and traditional risk factors have been proposed¹⁴,¹⁵ and have been proved to be reasonably accurate in preliminary studies of HIV-infected men and women. The Framingham model, however, appears to underestimate CHD events in HIV patients who also smoke.¹⁴ Further validation of the Framingham risk equation and development of more accurate HIV-specific equations for risk stratification are needed, but the existing equations may nonetheless be useful for providing a general estimate of risk (see Development of Appropriate Coronary Heart Disease Risk Prediction Models in HIV-Infected Patients, Working Group 5).

Choice of Noninvasive Stress Tests

The use of graded levels of stress to elicit myocardial ischemia forms the cornerstone of noninvasive testing for...
CHD. Graded stress typically is applied in the form of physical exercise (using a treadmill or stationary bicycle) or pharmacological agents (using dipyridamole, dobutamine, or adenosine). Myocardial ischemia can be detected with standard 12-lead ECG, echocardiography, or nuclear imaging. The treadmill exercise ECG test, the most commonly used and least expensive stress test, has a mean sensitivity and specificity for detecting angiographically significant CHD of 68% and 77%, respectively. In patients with resting ST-segment abnormalities, left ventricular hypertrophy, left bundle-branch block, a ventricular paced rhythm, or the Wolff-Parkinson-White syndrome, an imaging study is preferred over exercise ECG. However, in a patient who is able to walk on a treadmill and has none of these ECG findings, pharmacological stress is recommended when patients are unable to perform adequate exercise. In patients with an intermediate pretest probability of CHD, the routinely used diagnostic tests (exercise ECG, planar thallium imaging, single-photon emission computed tomography perfusion imaging, stress echocardiography, and positron emission tomography) have sensitivities in the range of 68% to 91% and specificities of 73% to 88%. In addition to their differences in sensitivity and specificity, these tests vary in the frequency of nondiagnostic test results, prognostic accuracy, relative cost, interobserver variability, and availability of local expertise to perform and interpret the tests.

The selection of the most appropriate initial noninvasive diagnostic test for CHD in women is an important challenge. The lower prevalence of CHD in women compared with men of the same age and a higher rate of false-positive ST-segment depression on exercise ECG contribute to this challenge. As a result, selection of an imaging stress test may be preferable to the standard stress ECG as the initial test in women with an intermediate pretest probability of CHD.

The sensitivity of exercise treadmill test, pharmacological stress imaging, and stress echocardiography in the HIV-infected population remains unknown. In a study of 99 asymptomatic HIV-infected individuals without known CHD, 11% were shown to have a positive stress test result, with 1 patient requiring coronary artery bypass graft surgery.

### Emerging Risk Factors for CHD

In the general population, the inflammatory response plays a critical role in all stages of atherogenesis from its inception to plaque rupture. Many factors suggest that HIV-infected individuals are at greater risk for CVD as a result of the HIV infection itself and/or synergistic interactions between side effects of some antiretroviral agents and predisposing traditional cardiovascular risk factors. Currently, the underlying mechanisms associated with CVD and HIV are not clearly understood (see also Contribution of Metabolic and Anthropometric Abnormalities to Cardiovascular Disease Risk Factors [Working Group 1] and Effects of HIV Infection and Antiretroviral Therapy on the Heart and Vasculature [Working Group 3]). However, several noninvasive surrogate biological markers (biomarkers) have been demonstrated to monitor the inflammatory process and lipid metabolism. Inflammatory biomarkers include proinflammatory cytokines, chemokines, products of hepatic circulation, and immunoglobulin molecules. Lipid biomarkers include the traditional lipid profile, other lipoproteins, LDL fractions, and HDL subfractions.

Of the inflammatory biomarkers, only high-sensitivity C-reactive protein (hsCRP) has been recommended for use in clinical practice by the Centers for Disease Control and Prevention (CDC) and the AHA. Epidemiological data have
shown that hsCRP has had the strongest association with prognosis for new cardiovascular events in patients with unstable angina and myocardial infarction. On the basis of the available evidence, the CDC/AHA suggest that patients with moderate risk (10% to 20% risk of CVD over 10 years) may benefit from measurement of hsCRP to identify individuals who should be considered for medical therapy (ie, lipid-lowering, antplatelet, or other cardioprotective drugs). In a cohort of HIV-infected women, CRP level was an independent predictor of mortality ($P<0.01$) after adjustment for age, body mass index, serum albumin, CD4 lymphocytes, and HIV-1 RNA. Data from the Multicenter AIDS Cohort Study showed that levels of CRP were associated with HIV disease progression independently of CD4 count and HIV RNA levels. Early studies suggest that increased CRP is a function of changes in fat distribution independently of viral load or CD4 count in HIV-infected women. For patients with HIV, the role of hsCRP in clinical practice is less clear because results could be confounded by comorbid health conditions, and studies investigating the relationship between CRP and CHD, controlling for traditional risk factors, are needed in the HIV population. Other biomarkers include adiponectin, serum amyloid A, vascular cell adhesion molecule-1, intracellular adhesion molecule-1, lipoprotein-associated phospholipase A$_{2}$, and monocyte chemotactic protein-1. Adiponectin is reduced in HIV-infected patients with fat redistribution and may contribute to insulin resistance. Although epidemiological studies suggest that these inflammatory biomarkers are unrelated to each other, in vitro and in vivo studies indicate that these markers are involved at different stages of atherosclerotic lesion formation. There are no data yet to suggest that use of these biomarkers adds to evaluation of CHD risk among HIV-infected patients in clinical practice. In addition, HIV-infected patients may have impaired fibrinolysis and thus may be at higher risk for thrombosis compared with uninfected patients.

Of the lipid biomarkers, apolipoprotein (apo) B has been discussed as a potential substitute for LDL-C and non–HDL-C in the screening and treatment of CVD. Some studies suggest that apoB is a stronger predictor of CVD than LDL-C and the combined ratio measurement of apoB and apoA-I is superior to any of the conventional cholesterol ratios (LDL-C/HDL-C, TC/HDL-C, non–HDL-C/HDL-C) in predicting the risk for CVD. The Insulin Resistance Atherosclerosis Study found that 10% of subjects had an apoB $>120$ mg/dL but did not have an elevated LDL-C or non–HDL-C, implying that current lipid guidelines may miss these individuals. However, the results of other large-scale prospective studies have not been consistent with regard to apoB and apoA-I. In the Atherosclerosis Risk in Communities Study, apoB and apoA-I were strongly predictive of CVD when considered alone but did not contribute when considered together with LDL-C, HDL-C, and triglycerides. The Goettingen Risk, Incidence and Prevalence Study found that LDL-C was a stronger predictor of myocardial infarction than the ratio of apoB to apoA-I or apo B. In light of these observations, the addition of the ratio of apoB to apoA-I to clinical measures should be considered a tool to fine-tune the risk assessment and targets of therapy. Among HIV-infected patients, use of PI is associated with an atherogenic lipid profile and increased apoB; thus, evaluation of apoB may prove useful to further define risk when LDL-C is normal and triglyceride levels are increased. In HIV-infected patients, treatment with lipid-lowering therapy has been shown to improve atherogenic lipid profiles (see also Prevention Strategies for Cardiovascular Disease in HIV-Infected Patients, Working Group 6).

Plasma levels of the amino terminal fragment of prohormone brain-type natriuretic peptide (NT-proBNP) are predictive of cardiovascular morbidity and mortality and can identify patients who are at risk for events in the future. A study of 495 HIV-infected individuals who were treated with HAART showed that these individuals had higher NT-proBNP levels compared with age-matched blood donors. Like hsCRP, the ability of NT-proBNP to predict cardiovascular events in HIV-infected individuals remains unclear and requires further studies.

**Surrogate Marker Studies of Atherosclerosis**

Surrogate markers for CVD serve as reasonable alternatives to defined cardiovascular end points in clinical studies, although each marker has limitations. Whether these markers are as useful for documenting CVD in the individual patient is less clear. The validated surrogate markers that predict cardiovascular outcomes include measurement of carotid intimal wall thickness (cIMT) and coronary calcium scores (CCS). Three large studies have demonstrated that cIMT was an independent predictor of coronary artery disease. Precise standardization of protocols for obtaining cIMT images and methods to ensure precise positioning are necessary for these measures to be valid in the assessment of atherosclerosis and in determining progression. In addition, the value of a single cIMT measurement is unclear, and it may be that the rate of progression over time is more valuable in determining CVD risk than a measure at a single point in time. Computed tomography can accurately and reproducibly quantify the presence of coronary calcium. Although the CCS correlates well with total atherosclerotic plaque burden, it reflects advanced (calcified) lesions. As such, it may be less useful as an indicator of clinical risk at early stages when risk-reduction interventions may be more successful.

Both of these surrogate markers have been studied in HIV-infected populations, typically to identify factors associated with CVD. In cross-sectional studies of cIMT, older age, male sex, smoking, and increased body mass index were associated with increased cIMT. One AIDS Clinical Trials Group study was uniquely designed with triads of patients enrolled simultaneously: HIV-infected patients with a history of PI use; HIV-infected patients with no PI exposure; and age-, sex-, ethnicity-, smoking history-, blood pressure-, and menopausal status–matched, HIV-negative control subjects. There was no correlation between PI use or HIV infection and cIMT, but traditional risk factors of age, HDL, and body mass index were associated. The sample size was small in all of these studies, and follow-up was limited in duration. In a longitudinal study,
Controversial Issues, Gaps in Knowledge, and Future Research Priorities

The extent to which HIV infection or its treatment alters the underlying pathophysiology and progression of atherosclerosis remains unresolved. Preclinical screening strategies that rely on the pretest likelihood of disease are still largely extrapolations from conventional risk factor profiles, and screening modalities may not perform as expected in this population. Furthermore, atypical symptoms of myocardial ischemia can delay diagnosis and affect outcomes, and it remains unknown whether ischemic symptomatology is atypical in HIV-infected patients or whether such patients have high rates of silent ischemia, as is seen in patients with diabetes mellitus. Several key areas for future research were identified:

- Define the sensitivity and specificity of diagnostic tests for coronary disease such as exercise or pharmacological stress testing, nuclear imaging, and stress echocardiography in HIV-infected patients.
- Determine the clinical utility of surrogate markers such as hsCRP, cIMT, coronary calcium, and flow-mediated vasodilatation of the brachial artery in the early detection of CHD in HIV-infected patients.
- Compare the spectrum of clinical presentations of angina and ischemia in patients with and without HIV to determine presentation patterns and silent ischemia rates in the HIV population. In this regard, determining the effects of age, gender, and race on ischemic symptomatology among HIV-infected patients is critical.
- Determine the long-term outcomes of HIV patients after coronary events and develop appropriate risk reduction and treatment strategies (eg, medical versus interventional) based on these data.

In the absence of HIV-specific studies, recommendations for both the screening and diagnosis of coronary artery disease in the HIV-infected individual do not differ generally from the strategies that have been proven effective in uninfected populations. The gaps in our knowledge base regarding best screening and treatment practices need careful ongoing clinical and basic study in large populations with long follow-up if we are to refine our approach to the detection and amelioration of CHD and other CVDs in the HIV-infected population.

Disclosures

Potential conflicts of interest for members of the writing groups for all sections of these conference proceedings are provided in a disclosure table included with the Executive Summary, which is available online at http://circ.ahajournals.org/cgi/content/full/CIRCULATIONAHA.107.189622.

References

Screening and Assessment of Coronary Heart Disease in HIV-Infected Patients
Priscilla Y. Hsue, Kathleen Squires, Ann F. Bolger, Bernadette Capili, George A. Mensah,
Zelalem Temesgen, Christine A. Wanke and David A. Wohl
for Working Group 4

_Circulation_. published online June 19, 2008;
_Circulation_ is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231
Copyright © 2008 American Heart Association, Inc. All rights reserved.
Print ISSN: 0009-7322. Online ISSN: 1524-4539

The online version of this article, along with updated information and services, is located on the
World Wide Web at:
http://circ.ahajournals.org/content/early/2008/06/19/CIRCULATIONAHA.107.189626.citation

**Permissions:** Requests for permissions to reproduce figures, tables, or portions of articles originally published in _Circulation_ can be obtained via RightsLink, a service of the Copyright Clearance Center, not the Editorial Office. Once the online version of the published article for which permission is being requested is located, click Request Permissions in the middle column of the Web page under Services. Further information about this process is available in the Permissions and Rights Question and Answer document.

**Reprints:** Information about reprints can be found online at:
http://www.lww.com/reprints

**Subscriptions:** Information about subscribing to _Circulation_ is online at:
http://circ.ahajournals.org/subscriptions/